The antiarthritic effect of CBR-470-1 in hypoxic environment is to increase the level of NOD-like receptor family pyrin domain containing 3 ubiquitination by decreasing phosphoglycerate kinase 1 activity

Abstract

	•Hypoxia plays a pro-inflammatory role by increasing PGK1 activity and thereby decreasing the ubiquitination level of NLRP3.
	•Hypoxia plays a pro-inflammatory role by increasing PGK1 activity, reducing the binding of the deubiquitinating enzyme USP14 to NLRP3, and reducing the ubiquitination level of NLRP3.
	•CBR-470-1 reverses the role of hypoxia in the progression of osteoarthritis.

Keywords

CBR-470-1 / hypoxia / NLRP3 / osteoarthritis / PGK1 / USP14

References

[1] Katz JN, Arant KR, Loeser RF. Diagnosis and treatment of hip and knee osteoarthritis: a review. JAMA. 2021;325:568-578.

[2] Cui A, Li H, Wang D, Zhong J, Chen Y, Lu H. Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies. EClinicalMedicine. 2020;29-30:100587.

[3] Lin J, Zhang W, Jones A, Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ. 2004;329:324.

[4] da Costa BR, Pereira TV, Saadat P, et al. Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis. BMJ. 2021;375:n2321.

[5] Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393:1745-1759.

[6] Long H, Zeng X, Liu Q, et al. Burden of osteoarthritis in China, 1990-2017: findings from the Global Burden of Disease Study 2017. Lancet Rheumatol. 2020;2:e164-e172.

[7] Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med. 2011;364:656-665.

[8] Melillo G. Hypoxia: jump-starting inflammation. Blood. 2011;117:2561-2562.

[9] Fagenholz PJ, Harris NS. Hypoxia and inflammation. N Engl J Med. 2011;364:1976. author reply 1977.

[10] van den Bosch MHJ. Osteoarthritis year in review 2020: biology. Osteoarthritis Cartilage. 2021;29:143-150.

[11] Boehme KA, Rolauffs B. Onset and progression of human osteoarthritis-can growth factors, inflammatory cytokines, or differential miRNA expression concomitantly induce proliferation, ECM degradation, and inflammation in articular cartilage? Int J Mol Sci. 2018;19:2282.

[12] Fernandes TL, Gomoll AH, Lattermann C, Hernandez AJ, Bueno DF, Amano MT. Macrophage: a potential target on cartilage regeneration. Front Immunol. 2020;11:111.

[13] Sanchez-Lopez E, Zhong Z, Stubelius A, et al. Choline uptake and metabolism modulate macrophage IL-1β and IL-18 production. Cell Metab. 2019;29:1350-1362. e1357.

[14] Hughes MM, O’Neill LAJ. Metabolic regulation of NLRP3. Immunol Rev. 2018;281:88-98.

[15] Yan Z, Qi W, Zhan J, et al. Activating Nrf2 signalling alleviates osteoarthritis development by inhibiting inflammasome activation. J Cell Mol Med. 2020;24:13046-13057.

[16] Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell. 2014;157:1013-1022.

[17] Xu T, Yu W, Fang H, et al. Ubiquitination of NLRP3 by gp78/Insig-1 restrains NLRP3 inflammasome activation. Cell Death Differ. 2022;29:1582-1595.

[18] Di Q, Zhao X, Tang H, et al. USP22 suppresses the NLRP3 inflammasome by degrading NLRP3 via ATG5-dependent autophagy. Autophagy. 2023;19:873-885.

[19] Park YJ, Dodantenna N, Kim Y, et al. MARCH5-dependent NLRP3 ubiquitination is required for mitochondrial NLRP3-NEK7 complex formation and NLRP3 inflammasome activation. Embo J. 2023;42:e113481.

[20] Xin X, Yang K, Liu H, Li Y. Hypobaric hypoxia triggers pyroptosis in the retina via NLRP3 inflammasome activation. Apoptosis. 2022;27:222-232.

[21] Zhu X, Liu H, Wang D, et al. NLRP3 deficiency protects against hypobaric hypoxia induced neuroinflammation and cognitive dysfunction. Ecotoxicol Environ Saf. 2023;255:114828.

[22] Chen D, Dixon BJ, Doycheva DM, et al. IRE1α inhibition decreased TXNIP/NLRP3 inflammasome activation through miR-17-5p after neonatal hypoxic-ischemic brain injury in rats. J Neuroinflammation. 2018;15:32.

[23] Bollong MJ, Lee G, Coukos JS, et al. A metabolite-derived protein modification integrates glycolysis with KEAP1-NRF2 signalling. Nature. 2018;562:600-604.

[24] Tang J, Tu S, Lin G, et al. Sequential ubiquitination of NLRP3 by RNF125 and Cbl-b limits inflammasome activation and endotoxemia. J Exp Med. 2020:217.

[25] Ren G, Zhang X, Xiao Y, et al. ABRO1 promotes NLRP3 inflammasome activation through regulation of NLRP3 deubiquitination. Embo J. 2019;38.

[26] Ren GM, Li J, Zhang XC, et al. Pharmacological targeting of NLRP3 deubiquitination for treatment of NLRP3-associated inflammatory diseases. Sci Immunol. 2021;6.

[27] Song H, Liu B, Huai W, et al. The E3 ubiquitin ligase TRIM31 attenuates NLRP3 inflammasome activation by promoting proteasomal degradation of NLRP3. Nat Commun. 2016;7:13727.

[28] Semenza GL. Life with oxygen. Science. 2007;318:62-64.

[29] Hackett PH, Roach RC. High-altitude illness. N Engl J Med. 2001;345:107-114.

[30] Grocott MP, Martin DS, Levett DZ, McMorrow R, Windsor J, Montgomery HE. Arterial blood gases and oxygen content in climbers on Mount Everest. N Engl J Med. 2009;360:140-149.

[31] Hartmann G, Tschöp M, Fischer R, et al. High altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and C-reactive protein. Cytokine. 2000;12:246-252.

[32] Rosenberger P, Schwab JM, Mirakaj V, et al. Hypoxia-inducible factor-dependent induction of netrin-1 dampens inflammation caused by hypoxia. Nat Immunol. 2009;10:195-202.

[33] Eckle T, Faigle M, Grenz A, Laucher S, Thompson LF, Eltzschig HK. A2B adenosine receptor dampens hypoxia-induced vascular leak. Blood. 2008;111:2024-2035.

[34] Eltzschig HK, Ibla JC, Furuta GT, et al. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med. 2003;198:783-796.

[35] Thompson LF, Eltzschig HK, Ibla JC, et al. Crucial role for ecto-5’-nucleotidase (CD73) in vascular leakage during hypoxia. J Exp Med. 2004;200:1395-1405.

[36] Eltzschig HK, Abdulla P, Hoffman E, et al. HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J Exp Med. 2005;202:1493-1505.

[37] Hunter DJ, March L, Chew M. Osteoarthritis in 2020 and beyond-Authors’ reply. Lancet. 2021;397:1060.

[38] Loeser RF, Collins JA, Diekman BO. Ageing and the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016;12:412-420.

[39] Chou CH, Jain V, Gibson J, et al. Synovial cell cross-talk with cartilage plays a major role in the pathogenesis of osteoarthritis. Sci Rep. 2020;10:10868.

[40] Klein-Wieringa IR, de Lange-Brokaar BJ, Yusuf E, et al. Inflammatory cells in patients with endstage knee osteoarthritis: a comparison between the synovium and the infrapatellar fat pad. J Rheumatol. 2016;43:771-778.

[41] Wood MJ, Leckenby A, Reynolds G, et al. Macrophage proliferation distinguishes 2 subgroups of knee osteoarthritis patients. JCI Insight. 2019;4:e125325.

[42] Daheshia M, Yao JQ. The interleukin 1beta pathway in the pathogenesis of osteoarthritis. J Rheumatol. 2008;35:2306-2312.

[43] Inoue H, Hiraoka K, Hoshino T, et al. High levels of serum IL-18 promote cartilage loss through suppression of aggrecan synthesis. Bone. 2008;42:1102-1110.

[44] McAllister MJ, Chemaly M, Eakin AJ, Gibson DS, McGilligan VE. NLRP3 as a potentially novel biomarker for the management of osteoarthritis. Osteoarthritis Cartilage. 2018;26:612-619.

[45] Zheng J, Zhu JL, Zhang Y, et al. PGK1 inhibitor CBR-470-1 protects neuronal cells from MPP+. Aging. 2020;12:13388-13399.

[46] Liu H, Shen L, Sun Z, Wu W, Xu M. Downregulated phosphoglycerate kinase 1 attenuates cerebral ischemia-reperfusion injury by reversing neuroinflammation and oxidative stress through the nuclear factor erythroid 2 related factor 2/ARE pathway. Neuroscience. 2023;524:94-107.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.